Orsiro® Mission DES

Even better deliverability for the outstanding Orsiro DES1

Find out how Orsiro Mission can benefit your daily practice.

LEARN MORE

Full System

The next level of deliverability1

The next level of deliverability1

1st in Push3
Transmitting up to 96% more force from hub to tip.

Proven deliverability on the bench and in a real-world user evaluation of over 1,000 implantations:4

Proven deliverability on the bench and in a real-world user evaluation of over 1,000 implantations:4

1st in Track3
Up to 33% less force needed to follow the path to the lesion.
1st in Cross3
Up to 64% less force needed to successfully cross demanding anatomies.

Ultrathin struts5

Ultrathin struts5

For early endothelialization

Strut thickness in perspective7

OrsiroBIOTRONIK

CoCr-SES, 60 μma

Synergy XDBoston Scientific

PtCr-EES, 74 μm

UltimasterTerumo

CoCr-SES, 80 μm

Resolute Onyx8,9Medtronic

CoNi-ZES, 81 μm

Xience FamilyAbbott

CoCr-EEs, 81 μm

PromusBoston Scientific

PtCr-EES, 81 μm

BioMatrixBiosensors

316L-BES, 120 μm

Outstanding patient outcomes10

Outstanding patient outcomes10

One of the most studied DES11

>

100,000

patients enrolled or
planned in total12

>

71,000

patients enrolled12

>

86

studies started12

Orsiro – the highest probability (70.8%) to rank as the best stentc
Taglieri et al. network meta-analysis (n = 99,039 patients, 77 RCTs)13

If we want to inform our clinical practice on the best evidence available, we have to acknowledge that at 1-year the best stent, is the Orsiro stent.”

Dr. Tullio Palmerini,
Policlinico S. Orsola, Malpighi,
Bologna, Italy

Pushing the boundaries of safety performance with Orsiroe
BIOFLOW-V (n = 1,334), 5-Year results of the FDA pivotal trial14

Orsiro Mission DES is indicated for complex patients and lesionsh

ACS

STEMI

DM

HBR

B2C

SV

MVD

Continued Superiority up to 5 years15,i

BIOSTEMI (n=1,300)

7.7%

Orsiro

11%

XIENCE

Target Lesion Failure (TLF) rate at 5 years.

Rate Ratio 0.70; 95% BCI, 0.51-0.95 Bayesian posterior probability, 0.988

Low stent thrombosis (ST) at 5 years16

BIO-RESORT Small Vessels (n=1,506)

n = number of struts analyzed
ACS – Acute Coronary Syndrome; STEMI – ST-Elevation Myocardial Infarction; DM – Diabetes Mellitus. HBR – High Bleeding Risk; B2C – Complex Lesions; SV – Small Vessels; MVD – Multi-Vessel Disease

a ø 2.25 – 3.0 mm; b Images: Secco G et al. Time-related changes in neointimal tissue coverage following a new generation SES implantation: an OCT observational study. Presented at: euro PCR, May 20, 2014; Paris, France; c Based on 1-year TLF SUCRA score, in comparison to Xience, Resolute and Nobori/BioMatrix, after a median follow-up period of 50 months; d Resolute Integrity and Resolute Onyx; e In comparison to Xience, based on statistically significant lower TV-MI and late/very late definite/probable ST rates from the BIOFLOW-V trial through 5 years; f p-values for 60-month frequentist analysis; g In comparison to Xience, based on BIOFLOW-V 5-year results; h As per IFU;  i Based on TLF primary endpoint, Iglesias J.F., BIOSTEMI 5 year follow up, Presented at TCT 2023, San Francisco USA Clinical data collected with the Orsiro DES device within the Orsiro family clinical program;  j BCI: Bayesian Credibility Interval; k n= 1,300 newly enrolled STEMI patients including 407 patients from the BIOSCIENCE STEMI subgroup used as prior information; l At 5-year in STEMI patients.  Based on TLF with Orsiro DES in comparison to Xience DES in STEMI patient; m In comparison to Resolute Integrity, based on 5-year results of the BIO-Resort trial SV subgroup.

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. Per investigators’ interpretation of preclinical studies with Orsiro as mentioned in Cassese et al. J Thorac Dis 2018;10(2):688-692; 3. BIOTRONIK data on file; 4. Evaluation of Market Acceptance, BIOTRONIK data on file; 5. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 6. Secco G et al. Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent: Serial observations with optical coherence tomography. Cardiovascular Revascularization Medicine 17.1 (2016): 38-43; 7. Stefanini GG et al. Coronary stents: novel developments. Heart. 2014 Jul 1;100(13):1051-61; 8. Low AF. Stent platform for procedural success: Introducing the Continuous Sinusoidal & Core Wire Technologies. Presented at: AsiaPCR; 22-24 January, 2015; Singapore, Singapore; 9. Tolentino A. Evolving DES Strategy: Biodegradable Polymer vs. Bioabsorbable Scaffold. Presented at: Cardiovascular Nurse/Technologist Symposium; June 17, 2016; New York, USA; 10. Based on investigator’s interpretation of BIOFLOW-V primary endpoint result; 11.Based on Taglieri et al. Meta-analysis, against currently used DES; 12. BIOTRONIK data on file, as of February 2023; 13. Taglieri N et al. Target lesion failure with current drug-eluting stents: Evidence from a comprehensive network meta-analysis. JACC 2020 13(24):2868-78; 14. Kandzari D et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Final 5-year Outcomes from the Randomized BIOFLOW V Trial, JACC, 2022: NCT02389946; 15. Iglesias J.F., BIOSTEMI 5 year follow up, Presented at TCT 2023, San Francisco USA. 16. Ploumen etal. BIO-RESORT Small Vessels 5Y-EuroPCR2022.

Clinical data collected with the Orsiro DES and/or Orsiro Mission DES device within the Orsiro family clinical program

Orsiro, Orsiro Mission, proBIO and BIOlute are trademarks or registered trademarks of the BIOTRONIK Group of Companies. Synergy, Synergy XD, Promus and Taxus are trademarks or registered trademarks of the Boston Scientific Group of Companies. Resolute, Integrity, Resolute Onyx and Resolute Integrity are trademarks or registered trademarks of the Medtronic Group of Companies. Xience and Xience Skypoint are trademarks or registered trademarks of the Abbott Group of Companies. Biofreedom and BioMatrix are trademarks or registered trademarks of the Biosensors International Group. Cre8 is a trademark or registered trademark of the Alvimedica Group of Companies. Nobori is a trademark or registered trademark of the Terumo Group of Companies. Cypher is a trademark or registered trademark of the Cardinal Health Group of Companies. 

© 2024 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.